Xonef drops eye bottles-drops 0.5% 5ml
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Betaxolol
Release form
Drops
Composition
1 ml contains betaxolol 5 mg; Excipients: benzalkonium chloride, hypromellose, sodium chloride, sodium hydroxide, disodium edetate, water d / and
Pharmacological effect
Antiglaucoma drug. Selective beta1-adrenergic blocker without internal sympathomimetic activity. Does not have a membrane stabilizing (local anesthetic) action. When applied topically, betaxolol reduces intraocular pressure by reducing the production of intraocular fluid. The onset of the hypotensive effect is observed 30 minutes after instillation, the maximum effect develops after 2 hours. .Betaxolol (compared with other beta-blockers) does not cause a decrease in blood flow in the optic nerve. The use of Xonef eye drops is not leads to the occurrence of miosis, accommodation spasm, hemeralopia (unlike miotics)
Pharmacokinetics
Betaxolol is highly lipophilic, as a result of which it penetrates well through the cornea into the anterior chamber of the eye. Cmax (1.17 mg / ml) in the anterior chamber is determined 20 minutes after instillation. It penetrates the systemic circulation. T1 / 2 from intraocular fluid about 1 h. T1 / 2 from blood plasma 16-22 h. Excretion mainly through the kidneys
Indications
As a monotherapy: - to reduce intraocular pressure. In combination with other drugs for: - open-angle glaucoma; - ocular hypertension.
Contraindications
Sinus bradycardia - AV-blockade II and III degrees - severe heart failure - cardiogenic shock - arterial hypotension - children under 18 years old - hypersensitivity to the components of the drug.With caution, you should use the drug for thyrotoxicosis, myasthenia, sugar diabetes, Raynaud's syndrome, pheochromocytoma, bronchial asthma, chronic obstructive bronchitis
Precautionary measures
Impact on the ability to drive vehicles and control mechanismsIf after applying the drops to patients, the clarity of vision temporarily decreases, until it is restored, it is not recommended to drive vehicles and engage in activities requiring increased attention and reaction
Use during pregnancy and lactation
Use of the drug during pregnancy and lactation (breastfeeding) is possible only if the intended benefit to the mother outweighs the potential risk to the fetus or child
Dosage and administration
Instill 1 drop 2 times a day in the affected eye. During the first month, the therapy is carried out under the control of the level of intraocular pressure, then the frequency of measuring intraocular pressure is determined individually. In the case of the use of Betaxolol after previous treatment with another similar drug, the dosing regimen is set individually
Side effects
On the part of the organ of vision: often - short-term discomfort in the eyes after instillation, lacrimation; in some cases - reduced sensitivity of the cornea, redness of the eyes, spot keratitis, photophobia, anisocoria, photophobia, itching, feeling of dry eyes, allergic reactions. depression, increased symptoms of myasthenia. From the side of the cardiovascular system: bradycardia, disturbance of cardiac conduction and heart failure. From the side of the respiratory system: dyspnea, bronchospasm, bronchial asthma, respirator Naya failure
Overdose
If an excessive amount of the drug gets into the eyes, the eyes should be washed with warm water. Symptoms: an overdose of beta1-adrenergic blockers may cause a decrease in blood pressure, bradycardia, and acute heart failure. Treatment: symptomatic therapy is performed
Interaction with other drugs
With simultaneous use of the drug Xonef and beta-blockers for oral administration increases the risk of side effects (both local and systemic) due to the additive effect (therefore, patients receiving this combination of drugs must be under medical supervision). When using the drug Xonef in combination with drugs that deplete catecholamine stores (such as reserpine), there may be a decrease in blood pressure and bradycardia. With the simultaneous appointment of muscle relaxants and hypoglycemic agents there is an increase in their action. When combined with sympathomimetics - an increase in their vasoconstrictive effect. Care should be taken when using Xonef and psychotropic drugs together because of a possible increase in their action.
special instructions
The drug is prescribed with caution to patients with diabetes mellitus, since beta-blockers may mask the symptoms of acute hypoglycemia. With caution, the drug is prescribed to patients with thyrotoxicosis, since beta-blockers may mask the symptoms of thyrotoxicosis (for example, tachycardia). In patients with suspected thyrotoxicosis, beta-blockers should not be abruptly discontinued, since this may cause increased symptoms. It should be borne in mind that beta-blockers can cause symptoms similar to those in myasthenia (diplopia, ptosis, general weakness). Be careful with beta-blockers in patients with severely impaired function of the respiratory system. Despite the fact that clinical studies have shown the absence of the effect of betaxolol in ophthalmic dosage form on the function of external respiration, it is impossible to exclude the possibility of increased sensitivity to the drug. During general anesthesia, they can reduce the sensitivity of the myocardium to sympathetic stimulation. Patients who use beta-blockers may have a history of atopy or anaphylactic reactions. In case of repeated hypersensitivity reactions, these patients may not be sensitive to the usual doses of epinephrine (adrenaline) needed to relieve anaphylaxis. The drug should be administered with caution to patients with Raynaud's syndrome or pheochromocytoma. . At the same time the same side effects can be noted, as well as at systemic use. Cases of severe respiratory and cardiovascular disorders, including fatal bronchospasm in patients with bronchial asthma and death from heart failure, have been described. Xonef has a minimal effect on blood pressure and heart rate. However, caution should be exercised in the appointment of the drug to patients with AV block I degree and mild to moderate heart failure. Treatment with Xoneuf should be stopped immediately when the first symptoms of decompensation appear on the part of the cardiovascular system. Xonef contains preservative benzalkonium chloride, which can be deposited on soft contact lenses and have a toxic effect on eye tissue.Therefore, patients wearing contact lenses should remove them before using the drops and set them back no earlier than 20 minutes after instillation